Delivery Order SPE2DB20D2002-SPE2DB23FL73T

Award Date 9/28/23
Potential Completion Date 9/29/23
Potential Value $1.3K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of RIZATRIPTAN 10 MG ODT UD 3S pharmaceutical products to the Defense Logistics Agency (DLA), a defense agency under the U.S. Department of Defense. The contract was awarded to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price type, valued at $95,673.52, and has an ultimate completion date of October 13, 2023. The...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,876.29 Delivery Order covers the supply of 4563282943 ! RIZATRIPTAN 5 MG ODT UD 3S, a prescription medication, with a period of performance ending on January 10, 2024. This award is associated with a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support...
This federal contract award, with ID SPE2DB20D7059|SPE2DB24FPXQ6, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RIZATRIPTAN 10 MG ODT UD 18S, a medical product, with a ceiling value of $3,276.22 and a completion date of January 17, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $49,750.34 firm fixed-price delivery order is for the supply of RIZATRIPTAN 10 MG ODT UD 3S, a pharmaceutical product, with an ultimate completion date of April 20, 2023. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award, valued at $1,466.11, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4,563,535,486 units of RIZATRIPTAN 10 MG ODT UD 18S, a pharmaceutical product. The contract has a period of performance through February 5, 2024 and was awarded on February 2, 2024 on a firm fixed-price basis. This contract does not have a set-aside designation, indicating open competition....
The federal contract award, valued at $26,465.04, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor, Amerisourcebergen Drug Corp, for the delivery of RIZATRIPTAN 5 MG ODT UD 3S. This award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, valued at $999,999,999 and running through November 2026. The IDC enables efficient government procurement of essential pharmaceutical and medical supplies to support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $24,980.91, is for the delivery of RIZATRIPTAN 10 MG ODT UD 3S, a pharmaceutical product. The contract is a Delivery Order, with a Firm Fixed Price pricing type, and has an ultimate completion date of May 10, 2023. The contract was not designated with a set-aside. AmerisourceBergen holds a...
This federal contract award, valued at $1,436.50, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is a Delivery Order for the supply of 4565111851 - RIZATRIPTAN 10 MG ODT UD 18S, a pharmaceutical product. The contract has a firm fixed-price pricing type and an ultimate completion date of July 11, 2024. Amerisourcebergen Drug Corp is a major supplier of pharmaceutical products and medical supplies to the U.S. federal...
This federal contract award, valued at $2,629.92, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is a delivery order for the supply of 4560665789 RIZATRIPTAN 10 MG TABLET UD 18S, and has an ultimate completion date of April 21, 2023. The contract is a firm fixed-price agreement with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The award, valued at $1,346.16, is a delivery order for the pharmaceutical product RIZATRIPTAN 10 MG ODT UD 18S. The contract does not have a set-aside designation, indicating it was awarded through full and open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
  • SPE2DB20D2002
    Indefinite Delivery Contract
  • SPE2DB20D2002-SPE2DB23FL73T
    Delivery Order

This federal contract award is for the delivery of RIZATRIPTAN 10 MG ODT UD 3S, a pharmaceutical product, by Amerisourcebergen Drug Corp to the Defense Logistics Agency (DLA). The contract has a ceiling value of $1,262.44 and a completion date of September 29, 2023. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical valued at up to $999,999,999.00. This IDC serves as the primary vehicle for Cencora, Inc. to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 2/27/25, 12:22 PM